High-profile investigator tapped to lead $10M prostate cancer program

Charles Sawyers, a high-profile cancer drug specialist at Memorial Sloan-Kettering Cancer Center, has been tapped to help lead a $10 million effort to test personalized treatments for prostate cancer. He and a "dream team" of clinical investigators will test various combination therapies, including abiraterone. Sawyers played a leading role in the discovery of MDV3100 and ARN-509, two closely watched prostate cancer treatments now in development. Story

 
Read more on